| Market Cap | 215.05Cr 188.55Cr 173.8Cr 162.72Cr 305.12Cr 20TCr 311.45Cr 2.09TCr 808.32Cr 10TCr 807.51Cr 789.87Cr 35TCr | P/E 2026 * |
-7.02x | P/E 2027 * | -5.75x |
|---|---|---|---|---|---|
| Enterprise Value | 215.05Cr 188.55Cr 173.8Cr 162.72Cr 305.12Cr 20TCr 311.45Cr 2.09TCr 808.32Cr 10TCr 807.51Cr 789.87Cr 35TCr | EV / Sales 2026 * |
52.2x | EV / Sales 2027 * | 58.3x |
| Free-Float |
99.55% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 67 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 215.05Cr | |
| +0.33% | +1.37% | +63.66% | +126.38% | 5.56TCr | |
| +0.82% | +15.05% | +79.52% | +85.53% | 5.22TCr | |
| +1.36% | +0.36% | -14.52% | -13.83% | 2.31TCr | |
| -1.04% | +7.91% | +3.91% | +417.68% | 2.24TCr | |
| -0.18% | +7.20% | +31.37% | -13.62% | 1.73TCr | |
| -1.10% | +4.00% | +29.97% | -33.36% | 1.59TCr | |
| +2.89% | +5.51% | +25.42% | +186.30% | 1.38TCr | |
| -3.35% | +8.96% | +134.32% | +289.59% | 1.35TCr | |
| +1.31% | +0.53% | +27.83% | - | 1.24TCr | |
| Average | +0.03% | +4.78% | +42.39% | +130.58% | 2.51TCr | |
| Weighted average by Cap. | +0.25% | +5.13% | +48.50% | +122.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.12Cr 3.61Cr 3.33Cr 3.12Cr 5.85Cr 388.83Cr 5.97Cr 40Cr 15Cr 192.17Cr 15Cr 15Cr 666.35Cr | 3.69Cr 3.24Cr 2.98Cr 2.79Cr 5.24Cr 348.15Cr 5.35Cr 36Cr 14Cr 172.06Cr 14Cr 14Cr 596.63Cr |
| Net income | -25Cr -22Cr -20Cr -19Cr -35Cr -2.36TCr -36Cr -242.88Cr -94Cr -1.17TCr -94Cr -92Cr -4.04TCr | -36Cr -31Cr -29Cr -27Cr -50Cr -3.36TCr -52Cr -345.62Cr -133.73Cr -1.66TCr -133.6Cr -130.68Cr -5.75TCr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
